ArticleFrontiers in oncology2026
Synchronous low-grade myofibroblastic sarcoma and small cell lung cancer in a patient with situs inversus totalis: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Situs inversus totalis (SIT) is a rare congenital anomaly. Its co-occurrence with multiple primary malignancies is exceedingly uncommon. Low-grade myofibroblastic sarcoma (LGMS) and small cell lung cancer (SCLC) represent two distinct neoplasms with markedly different biological behaviors and treatment sensitivities. To our knowledge, the synchronous presentation of LGMS and SCLC in a patient with SIT has not been previously described. Case presentation: A 72-year-old man with known SIT presented with respiratory symptoms. Imaging revealed a left hilar mass causing obstructive atelectasis, along with metastatic lymphadenopathy in cervical and inguinal regions. Pathological assessment confirmed synchronous extensive-stage SCLC (ES-SCLC) and cervical LGMS. Given the high chemosensitivity of SCLC, a sequential treatment strategy was implemented. The patient first received two cycles of induction chemoimmunotherapy with etoposide/cisplatin plus tislelizumab, which resulted in resolution of metastatic lymph nodes. This was followed by surgical resection of the residual cervical LGMS and four cycles of consolidation chemoimmunotherapy. Subsequent management included sequential thoracic radiotherapy and maintenance immunotherapy with tislelizumab. Conclusion: This report presents the first documented case of synchronous LGMS and SCLC in a patient with SIT. Our experience suggests that a biology-driven sequential approach, prioritizing systemic therapy for chemosensitive SCLC followed by local control of LGMS, can achieve a initial favorable response. It also underscores that radiotherapy remains feasible in SIT following detailed anatomical evaluation. This case offers a clinically applicable, biology-guided sequential strategy for managing synchronous malignancies with divergent treatment sensitivities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.